Full-Time
Global provider of integrated clinical-to-commercial services
No salary listed
Remote in Australia
Remote
Remote within Australia; pre-approved
Bachelor's
See people who can refer or advise you
Syneos Health provides end-to-end biopharmaceutical solutions across the clinical-to-commercial spectrum. It helps biopharma companies, healthcare organizations, and investors by offering specialized expertise, insights, and technology-enabled services to move therapies faster to patients. Its offerings include Kinetic, a modern omnichannel customer engagement platform that uses targeting and analytics to coordinate nationwide healthcare communications, and Syneos One, an asset development approach that aligns strategy and execution from early concept through commercialization. The company uses AI and advanced tech to improve performance and reduce risk in drug development and market delivery. Its goal is to be a trusted partner that accelerates therapy development and delivery by combining scientific know-how with integrated, data-driven services.
Company Size
10,001+
Company Stage
IPO
Headquarters
Morrisville, North Carolina
Founded
1985
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Employee Stock Purchase Plan
Flexible Work Hours
Paid Vacation
Paid Sick Leave
Remote Work Options
Helio Genomics has partnered with Syneos Health to accelerate nationwide adoption of HelioLiver, an AI-powered blood test for early liver cancer detection. Syneos Health will deploy field engagement and educational initiatives to reach hepatologists and gastroenterologists managing high-risk populations across the United States. HelioLiver combines cell-free DNA methylation patterns, protein biomarkers and patient demographics using proprietary AI algorithms. In the CLiMB trial involving nearly 1,968 patients across 50 clinical sites, the test demonstrated four times greater sensitivity for Stage I liver cancer compared to ultrasound. The test is reimbursed by Medicare at $662. The partnership builds on Helio Genomics' recent collaboration with Quest Diagnostics, providing access to over 7,700 patient service centres nationwide. Liver cancer incidence rates have tripled in the US since 1980.
KAI Conversations announces strategic partnership with Syneos Health to advance U.S. Pharmaceutical commercialization. GlobeNewswire | Syneos Health, Inc. Today at 9:30am PDT LONDON, April 30, 2026 (GLOBE NEWSWIRE) - KAI Conversations, an AI-powered conversation intelligence platform purpose-built for the pharmaceutical industry, today announced a strategic partnership with Syneos Health(R), a leading fully integrated biopharmaceutical solutions organization, to bring AI-driven field insights to the U.S. biopharma market. Pharmaceutical companies invest an estimated 30-50% of revenue in field teams, yet the majority of HCP interactions fail to translate into meaningful impact. This collaboration is designed to address that gap by helping companies turn everyday field conversations into actionable insights, more effective engagement and stronger brand performance. Through this strategic partnership, Syneos Health will embed KAI's platform into its commercial solutions - among the broadest in the industry - further strengthening the Company's ability to optimize field execution, accelerate behavior change and translate data-driven signals into measurable performance gains. KAI's platform, used by 10 of the top 20 global pharmaceutical companies across 15 therapeutic areas and multiple continents, analyzes conversations between field teams and healthcare professionals (HCPs). The platform delivers coaching to individual sales representatives while generating aggregated brand and customer intelligence for commercial and medical leaders. "The U.S. market represents a critical opportunity for pharmaceutical innovation and commercialization," said David Williams, Founder and CEO of KAI Conversations. "Partnering with Syneos Health enables us to scale our conversation intelligence through a trusted commercialization leader - equipping field teams with contextual coaching and insights to drive HCP engagement and stronger brand outcomes." "For years, valuable field insights were effectively invisible, locked inside everyday HCP conversations," said Paul Mignon, Head of Deployment Solutions at Syneos Health. "With KAI, we're surfacing real-time signals so our expert teams can optimize what works, predict what matters and automate next-best actions - driving precision performance to accelerate launch, adoption and growth." Together KAI and Syneos Health are advancing pharmaceutical commercialization by aligning AI-powered insights with integrated strategy, commercial execution and performance optimization. About KAI Conversations KAI Conversations is the world's leading AI conversation intelligence platform purpose-built for the pharmaceutical industry. The platform reveals previously hidden human insights by analyzing conversations between pharmaceutical field teams and healthcare professionals. By providing actionable insights and coaching, KAI empowers individuals and central teams to drive more effective engagement, enhance commercial outcomes, and accelerate brand performance. For more information, visit kaiconversations.com. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.
North Carolina-based contract research organization Syneos Health is making a play to capitalize on China’s rapidly ascendant biopharma industry. | North Carolina-based contract research organization Syneos Health is making a play to capitalize on China’s rapidly ascendant biopharma industry. Syneos has acquired Chinese CRO Bestudy to secure a foothold in the Asian nation.
Voyles joins Imre from Syneos Health, where he served as VP of commercial solutions.
Sunway Healthcare Group has partnered with Syneos Health to expand clinical trial capabilities across therapeutic areas in Malaysia.